
Aptevo's Mipletamig Demonstrates 86% Clinical Benefit in Frontline AML Treatment with Favorable Safety Profile
Aptevo Therapeutics' investigational therapy mipletamig, when combined with standard care, shows an 86% clinical benefit rate in frontline AML patients, offering potential for improved outcomes with limited toxicity in a difficult-to-treat cancer.
Read full story























